Article Text

Download PDFPDF
Routine Clinical Practice for Patients With Recurrent Ovarian Carcinoma: Results From the TROCADERO Study
  1. Gilles Freyer, MD, PhD*,
  2. Isabelle Ray-Coquard, MD, PhD,
  3. Dorothea Fischer, MD,
  4. Antonio González Martín, MD, PhD§,
  5. Adrian Kielhorn, MBA,
  6. Victoria Chia, MPH, PhD,
  7. Nuwan Nanayakkara, PhD and
  8. Aliki Taylor, MPH, PhD#
  1. *Institut de Cancérologie des HCL and
  2. Centre Léon Bérard, Université de Lyon, Lyon, France;
  3. Universitätsklinikum Schleswig-Holstein, Klinik für Frauenheilkunde und Geburtshilfe, Campus Lübeck, Lübeck, Germany;
  4. §MD Anderson Cancer Center, Madrid, Spain;
  5. Amgen Inc., Thousand Oaks; and
  6. Quintiles, San Diego, CA; and
  7. #Amgen Inc., Uxbridge, United Kingdom.
  1. Address correspondence and reprint requests to Gilles Freyer, MD, PhD, Service d’oncologie médicale, Centre Hospitalier Lyon-Sud, 69495 Pierre-Bénite cédex, France. E-mail: gilles.freyer@univ-lyon1.fr.

Abstract

Objective Treatment options for patients with recurrent ovarian carcinoma are diverse, and different therapies are recommended based on platinum-free interval (PFI). Data examining the association between platinum sensitivity, treatment strategy, and outcomes are limited, particularly for partially platinum-sensitive (PPS) patients. This study characterized clinical features and outcomes in patients with recurrent ovarian carcinoma in the context of sensitivity to platinum-based therapy.

Methods Anonymized case records were obtained from eligible European medical sites. Eligible patients were 18 years or older with epithelial ovarian carcinoma who had received 1 or more platinum-based therapies and had 1 or more subsequent relapses. Patient records were categorized by PFI and analyzed based on demographic and clinical data using descriptive statistics.

Results There was no difference between PFI in PPS patients receiving platinum versus nonplatinum therapy (8.9 [range, 6.0–12.0] and 8.3 [range, 6.0–11.3] months, respectively). Overall survival in patients with platinum-sensitive, PPS, platinum-resistant, and platinum-refractory disease was 43.0 (95% confidence interval [95% CI], 25.1–42.3), 20.5 (95% CI, 17.7–24.8), 12.7 (95% CI, 10.4–14.2), and 9.8 (95% CI, 6.6–14.9) months, respectively. Among PPS patients, overall survival was 23.5 (95% CI, 18.4–37.3) and 18.7 (95% CI, 11.0–23.5) months for those who received platinum and nonplatinum-based therapy, respectively. No demographic or clinical characteristics were identified that indicated a difference between PPS patients who received platinum-based therapy versus those who did not.

Conclusions Partially platinum-sensitive patients with recurrent ovarian carcinoma who received platinum-based therapy had improved outcomes compared with those who did not. No clear demographic criteria for choosing platinum- versus nonplatinum-based therapy for PPS patients were identified from patient records.

  • Ovarian cancer
  • Platinum compounds
  • Taxane
  • Recurrence
  • Outcomes research

Statistics from Altmetric.com

Footnotes

  • This work was funded by Amgen Inc.

  • G.F. has consulted for Amgen France. N.N. has performed contract work for Amgen Inc. A.T. is an employee of Amgen Ltd., Uxbridge, United Kingdom. V.C. and A.K. are employees of Amgen Inc., Thousand Oaks, CA, USA. A.T., V.C., and A.K. hold stock in Amgen Inc. I.R.-C., D.F., and A.G.-M. declare no conflicts of interest.

  • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.